Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Lebherz, Corinna ^a   Kahles, Florian ^a   Piotrowski, Katja ^d   Vogeser, Michael ^b   Foldenauer, Ann Christina ^a   Nassau, Kirsten ^c   Kilger, Erich ^c   Marx, Nikolaus ^a   Parhofer, Klaus G ^b   Lehrke, Michael ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Department of Internal Medicine II ^*  (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cardiac surgery; GLP 1; IL6; Inflammation; Inflammatory response; Insulin secretion

Indexed keywords

ADIPONECTIN; ADRENALIN; C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; IL6 PROTEIN, HUMAN;

AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART SURGERY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INFLAMMATION; INFUSION RATE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; KINETICS; LEAST SQUARE ANALYSIS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; RISK FACTOR; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOMARKERS; BLOOD GLUCOSE; CARDIAC SURGICAL PROCEDURES; CASE-CONTROL STUDIES; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROCORTISONE; INFLAMMATION; INSULIN; INTERLEUKIN-6; KINETICS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; UP-REGULATION;

EID: 84957439021     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0330-8     Document Type: Article

References (24)

1. Van Cromphaut SJ, Vanhorebeek I, Van den Berghe G. Glucose metabolism and insulin resistance in sepsis. Curr Pharm Des. 2008;14(19):1887-99.
2. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz). 2013;61(2):119-25.
3. Lang CH, Dobrescu C. Sepsis-induced increases in glucose uptake by macrophage-rich tissues persist during hypoglycemia. Metabolism. 1991;40(6):585-93.
4. Yelich MR, Filkins JP. Mechanism of hyperinsulinemia in endotoxicosis. Am J Physiol. 1980;239(2):E156-61.
5. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab. 2000;85(10):3770-8.
6. Kahles F, Meyer C, Mollmann J, Diebold S, Findeisen HM, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N, et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes. 2014;63(10):3221-9.
7. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57.
8. Lehrke M, Broedl UC, Biller-Friedmann IM, Vogeser M, Henschel V, Nassau K, Goke B, Kilger E, Parhofer KG. Serum concentrations of cortisol, interleukin 6, leptin and adiponectin predict stress induced insulin resistance in acute inflammatory reactions. Crit Care. 2008;12(6):R157.
9. Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, Leber AW, Becker A, Laubender RP, Lebherz C, et al. Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol. 2013;12:117.
10. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993;55(2):552-9.
11. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002;21(2):232-44.
12. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481-9.
13. Daousi C, Pinkney JH, Cleator J, Wilding JP, Ranganath LR. Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state? Regul Pept. 2013;183:54-61.
14. Lehrskov-Schmidt L, Lehrskov-Schmidt L, Nielsen ST, Holst JJ, Moller K, Solomon TP. The effects of TNF-alpha on GLP-1-stimulated plasma glucose kinetics. J Clin Endocrinol Metab. 2015;100(4):E616-22.
15. Claustre J, Brechet S, Plaisancie P, Chayvialle JA, Cuber JC. Stimulatory effect of beta-adrenergic agonists on ileal L cell secretion and modulation by alpha-adrenergic activation. J Endocrinol. 1999;162(2):271-8.
16. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes. 2003;52(2):252-9.
17. Galiatsatos P, Gibson BR, Rabiee A, Carlson O, Egan JM, Shannon RP, Andersen DK, Elahi D. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med. 2014;42(3):638-45.
18. Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med. 2010;38(5):1261-9.
19. Steven S, Hausding M, Kroller-Schon S, Mader M, Mikhed Y, Stamm P, Zinssius E, Pfeffer A, Welschof P, Agdauletova S, et al. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol. 2015;110(2):6.
20. Ceriello A, Esposito K, La Sala L, Pujadas G, De Nigris V, Testa R, Bucciarelli L, Rondinelli M, Genovese S. The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2014;13:140.
21. Ceriello A, Novials A, Canivell S, La Sala L, Pujadas G, Esposito K, Testa R, Bucciarelli L, Rondinelli M, Genovese S. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care. 2014;37(7):1938-43.
22. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism. 2014;63(9):1141-8.
23. Zeng Y, Li C, Guan M, Zheng Z, Li J, Xu W, Wang L, He F, Xue Y. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol. 2014;13:32.
24. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59(4):1030-7.